Skip to main content
SpringerLink
Log in

Psychopharmaka

  • Chapter
Arzneiverordnungs-Report 2004

  • 68 Accesses

Zusammenfassung

Die Verordnungsstruktur der Psychopharmaka hat sich in den letzten 10 Jahren auffällig verändert. Die Verordnungen der früher führenden Tranquillantien sind 2003 weiter rückläufig. Umgekehrt haben sich die Anti-depressivaverordnungen seit 1994 mehr als verdoppelt. Dieser Trend setzte sich 2003 durch die Anstiege bei den selektiv wirkenden Antidepressiva fort (+22%), Demgegenüber haben sich Neuroleptika auf fast konstantem Niveau gehalten. Allerdings haben sich die Verordnungen atypischer Neuroleptika mit geringerer Störung der Motorik weiter kräftig erhöht (+20%), während klassische hochpotente Neuroleptika weniger eingesetzt wurden (−5%). Pflanzliche Psychopharmaka sind erneut rückläufig (−12%).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Abraham J (2003): The science and politics of medicines control. Drug Saf 26: 135–143.

    Article  PubMed  Google Scholar 

  • Anonym (2003): Lithium-Therapie bei der manisch-depressiven Erkrankung: Immer noch der Standard? Arzneimittelbrief 37:49–51.

    Google Scholar 

  • Apter JT, Allen LA (1999): Buspirone: future directions. J Clin Psychopharmacol 19: 86–93.

    Article  PubMed  CAS  Google Scholar 

  • Arzneimittelkommission der deutschen Apotheker (2002): BfArM-Bescheid zu Kava-Kava. Pharm Ztg 147:6–7.

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (Hrsg) (1997): Empfehlungen zur Therapie der Depression. 1. Aufl. Sonderheft Arzneiverordnung in der Praxis. September 1997.

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (Hrsg) (2003): Empfehlungen zur Therapie von Angst-und Zwangsstörungen. 2. Aufl. Sonderheft Arzneiverordnung in der Praxis.

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (2001): Hepatotoxizität des neuen Antidepressivums Nefazodon (Nefadar?). Dtsch Ärztebl 98: B52.

    Google Scholar 

  • Baptista T, Lacruz A, Angeles F, Silvera R, de Mendoza S, Mendoza MT et al (2001): Endocrine and metabolic abnormalities involved in obesity associated with typical antipsychotic drug administration. Pharmacopsychiatry 34: 223–231.

    Article  PubMed  CAS  Google Scholar 

  • Barbenel DM, Yusufi B, O’Shea D, Bench CJ (2000): Mania in a patient receiving testosterone replacement postorchidectomy taking St John’s wort and sertraline. J Psychopharmacol 14: 84–86.

    Article  PubMed  CAS  Google Scholar 

  • Barbui C, Hotopf M (2001): Amitriptyline vs. the rest: still the leading antidepressant after 40 years of randomised controlled trials. Brit J Psychiatry 178:129–144.

    Article  CAS  Google Scholar 

  • Barbui C, Hotopf M, Freemantle N, Boynton J, Churchill R, Eccles MP et al (2000): Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence. Cochrane Database Syst Rev 2000(4): CD002791.

    Google Scholar 

  • Bauer M, Dopfner S (1999): Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 19: 427–434.

    Article  PubMed  CAS  Google Scholar 

  • Bauer M, Whybrow PC, Angst C, Verslani M, Möller H-J (2002): World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of unipolar depressive disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 3: 5–43.

    Article  PubMed  Google Scholar 

  • Baumann P (1996): Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 31:444–469.

    Article  PubMed  CAS  Google Scholar 

  • Benkert O, Szegedi A, Kohnen R (2000): Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 61: 656–663.

    Article  PubMed  CAS  Google Scholar 

  • Berlin I, Lecrubier Y (1996): Food and drug interactions with monoamine oxidase inhibitors: How safe are the newer agents? CNS Drugs 5:403–413.

    Article  CAS  Google Scholar 

  • Berner MM, Riemann D, Berger M (2002): The efficacy of hypericum extracts with more than 1% or less than 0.5% hyperforin content compared to placebo in the treatment of major depression — a systematic review and analysis of randomized controlled trials. Eur Arch Psychiatry Clin Neurosci 252(suppl 1): P230 (Abstract).

    Google Scholar 

  • Birmes P, Coppin D, Schmitt L, Lauque D (2003): Serotonin syndrome: a brief review. CMAJ 168:1439–1442.

    PubMed  Google Scholar 

  • Bon S, Hartmann K, Kuhn M (1999): Johanniskraut: Ein Enzyminduktor? Schweiz Ap Ztg 16: 535–536.

    Google Scholar 

  • Braun M, Strasser RH (1997): Trizyklische Antidepressiva und kongestive Kardio-mypathie. Internist 38:1236–1238.

    PubMed  CAS  Google Scholar 

  • Caley CF, Weber SS (1995): Sulpiride: an antipsychotic with selective dopaminergic antagonist properties. Ann Pharmacother 29:152–160.

    PubMed  CAS  Google Scholar 

  • Carriere P, Bonhomme D, Lemperiere T (2000): Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). Eur Psychiatry 15: 321–329.

    Article  PubMed  CAS  Google Scholar 

  • Carter CS, Mulsant BH, Sweet RA, Maxwell RA, Coley K et al (1995): Risperidone use in a teaching hospital during its first year after market approval: economic and clinical implications. Psychopharmacol Bull 31: 719–25.

    PubMed  CAS  Google Scholar 

  • Carvajal GP, Garcia D, Sanchez SA, Velasco MA, Rueda D, Lucena ML (2002): Hepatotoxicity associated with the new antidepressants. J Clin Psychiatry 63: 135–137.

    Article  Google Scholar 

  • Chick J, Howlett H, Morgan MY, Ritson B (2000): United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol 35: 176–187.

    PubMed  CAS  Google Scholar 

  • Chouinard G, Jones B, Remington G, Bloom D, Addington D et al (1993): A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13: 25–40.

    Article  PubMed  CAS  Google Scholar 

  • Colonna L, Saleem P, Dondey-Nouvel L, Rein W (2000): Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. Int Clin Psychopharmacol 15:13–22.

    Article  CAS  Google Scholar 

  • Correll CU, Leucht S, Kane JM (2004): Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 161:414–425.

    Article  PubMed  Google Scholar 

  • Csernansky JG, Mahmoud R, Brenner R (2002): A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 346: 16–22.

    Article  PubMed  CAS  Google Scholar 

  • Dardennes R, Even C, Bange F, Heim A (1995): Comparison of carbamazepine and lithium in the prophylaxis of bipolar disorders — a metaanalysis. Brit J Psychiat 166:378–381.

    Article  PubMed  CAS  Google Scholar 

  • Davis JM, Chen N, Glick ID (2003): A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60: 553–564.

    Article  PubMed  CAS  Google Scholar 

  • De Abajo FJ, Rodriguez LAG, Montero D (1999): Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. Brit Med J 319:1106–1109.

    Article  PubMed  Google Scholar 

  • De Smet PAGM, Touw DJ (2000): Safety of St John’s wort (Hypericum perforatum). Lancet 355:575–576.

    Article  PubMed  Google Scholar 

  • Dettling M, Hellweg R, Cascorbi I, Deichle U, Weise L, Müller-Oerlinghausen B (1999): Genetic determinants of drug-induced agranulocytosis: potential risk of olanzapine? Pharmacopsychiatry 32:32:110–112.

    Article  PubMed  CAS  Google Scholar 

  • Di Carlo G, Borreli F, Ernst E, Izzo AA (2001): St John’s wort: Prozac from the plant kingdom. Trends Pharmacol Sci 22: 292–297.

    Article  PubMed  Google Scholar 

  • Dinan TG (2002): Lithium in bipolar mood disorder. Evidence suggests that lithium should still be first choice for prophylactic treatment. Brit Med J 324: 988–989.

    Article  Google Scholar 

  • Donovan S, Clayton A, Beeharry M, Jones S, Kirk C, Waters K et al (2000): Deliberate self-harm and antidepressant drugs. Investigation of a possible link. Br J Psychiatry 177:551–556.

    Article  PubMed  CAS  Google Scholar 

  • Dose M (2003): Was ist der Stellenwert atypischer Neuroleptika für die Praxis? Arzneiverordnung in der Praxis 30, Heft 3: 5–6.

    Google Scholar 

  • Duggan L, Fenton M, Dardennes RM, El-Dosoky A, Indran S (2000): Olanzapine for schizophrenia. Cochrane Database Syst Rev 2: CD001359.

    Google Scholar 

  • Einarson TR, Arikian SR, Casciano J, Doyle JJ (1999): Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic anti-depressants in the treatment of depression: a meta-analysis of randomized controlled trials. Clin Ther 21: 296–308.

    Article  PubMed  CAS  Google Scholar 

  • Elliger T, Englert E, Freisleder FJ, Friedrich M, Gierow B et al (1994): Zur Behandlung schizophrener Psychosen des Kindes-und Jugendalters mit Clozapin (Leponex). Konsensuskonferenz vom 4. März 1994, Kinder und Jugendpsychiatrie. Z Kinder-Jugendpsychiat 22:325–327.

    Google Scholar 

  • Elliger TJ, Trott GE, Nissen G (1990): Prevalence of psychotropic medication in childhood and adolescence in the Federal Republic of Germany. Pharmacopsychiatry 23: 38–44.

    Article  PubMed  CAS  Google Scholar 

  • Ener RA, Meglathery SB, van Decker WA, Gallagher RM (2003) Serotonin syndrome and other serotonergic disorders. Pain Medicine 4:63–74.

    Article  PubMed  Google Scholar 

  • Ernst E (2000): Second thoughts about safety of St. John’s wort. Lancet 354: 2014–2016.

    Article  Google Scholar 

  • Ferguson JM, Wesnes KA, Schwartz GE (2003) Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. Int Clin Psychopharmacol 18:9–14.

    Article  PubMed  Google Scholar 

  • Franchini L, Zanardi R, Gasperini M, Perez J, Smeraldi E (1996): Fluvoxamine and lithium in long-term treatment of unipolar subjects with high recurrence rate. J Affect Disord 38:67–69.

    Article  PubMed  CAS  Google Scholar 

  • Frank E, Kupfer DJ, Perel JM (1990): Three-years outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 47:1093–1099.

    Article  PubMed  CAS  Google Scholar 

  • Gale C, Oakley-Browne M (2000) Anxiety disorder. Brit Med J 321:1204–1207.

    Article  PubMed  CAS  Google Scholar 

  • Geddes J, Freemantle N, Harrison P et al (2000): Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Brit Med J 321:1371–1376.

    Article  PubMed  CAS  Google Scholar 

  • Geddes JR, Freemantle N, Mason J, Eccles MP, Boynton J (2001): SSRIs versus other antidepressants for depressive disorder. Update Software Ltd Oxford, The Cochrane Library — Issue 1.

    Google Scholar 

  • Geiselmann B, Linden M (1991): Prescription and intake patterns in long-term and ultra-long-term benzodiazepine treatment in primary care practice. Pharmacopsychiatry 24: 55–61.

    Article  PubMed  CAS  Google Scholar 

  • Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E (2000): Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA 283: 3082–3088.

    Article  PubMed  CAS  Google Scholar 

  • Goodnick PJ, Barrios CA (2001): Use of olanzapine in non-psychotic psychiatric disorders. Expert Opin Pharmacother 2:667–680.

    Article  PubMed  CAS  Google Scholar 

  • Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D (2003): Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 290:1467–1473.

    Article  PubMed  CAS  Google Scholar 

  • Goodwin GM, Bowden CL, Calabrese JR, Grunze H, Kasper S et al (2004): A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 65: 432–441.

    Article  PubMed  CAS  Google Scholar 

  • Greil W, Ludwig-Mayerhofer W, Erazo N, Engel RR, Czernik A et al (1996): Comparative efficacy of lithium and amitriptyline in the maintenance treatment of recurrent unipolar depression: a randomised study. J Affect Disord 40:179–190.

    Article  PubMed  CAS  Google Scholar 

  • Guelfi JD, Ansseau M, Timmerman L, Korsgaard S (2001): Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol 21:425–431.

    Article  PubMed  CAS  Google Scholar 

  • Guzelcan Y, Scholte WF, Assies J, Becker HE (2001): Mania during the use of a combination preparation with St. John’s wort (Hypericum perforatum). Ned Tijdschr Geneeskd 6:1943–1945.

    Google Scholar 

  • Healy D (2003): Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychother Psychosom 72: 71–79.

    Article  PubMed  Google Scholar 

  • Hypericum Depression Trial Study Group (2002): Effect of Hypericum perforatum (St John’s Wort) in major depressive disorder. JAMA 287:1807–1814.

    Article  Google Scholar 

  • Johne A, Brockmöller J, Bauer S, Maurer A, Langheinrich M, Roots I (1999): Pharmacokinetic interaction of digoxin with an herbal extract from St. John’s wort (Hypericum perforatum). Clin Pharmacol Ther 66: 338–345.

    Article  PubMed  CAS  Google Scholar 

  • Johne A, Schmider J, Brockmöller J, Stadelmann AM, Stormer E, Bauer S et al (2002): Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John’s wort (Hypericum perforatum). J Clin Psychopharmacol 22: 46–54.

    Article  PubMed  CAS  Google Scholar 

  • Jureidini JN, Doecke CJ, Mansfield PR, Haby MM, Menkes DB, Tonkin AL (2004): Efficacy and safety of antidepressants for children and adolescents. BMJ 328: 879–883.

    Article  PubMed  CAS  Google Scholar 

  • Kane J, Honigfeld G, Singer J, Meltzer H (1988): Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45: 789–796.

    Article  PubMed  CAS  Google Scholar 

  • Kane JM, Eerdekens M, Lindenmayer JP, Keith S J, Lesem M, Karcher K (2003): Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 160:1125–1132.

    Article  PubMed  Google Scholar 

  • Kappler J, Menges C, Ferbert A, Ebel H (1994): Schwere „Spät“ dystonie nach „Neuroleptanxiolyse“ mit Fluspirilen. Nervenarzt 65:66–68.

    PubMed  CAS  Google Scholar 

  • Kasper S (1996): Mirtazapin. Klinisches Profil eines noradrenalin-und serotonin-spezifischen Antidepressivums. Arzneimitteltherapie 14(9): 257–259.

    Google Scholar 

  • Kimko HC, Cross JT, Abernethy DR (1999): Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmakokinet 37:457–470.

    Article  CAS  Google Scholar 

  • Knopf H, Melchert H-U (2003): Bundes-Gesundheitssurvey: Arzneimittelgebrauch. Robert-Koch-Institut Berlin (Hrsg).

    Google Scholar 

  • Kornhuber J (1994): Potentielle Antipsychotica mit neuartigen Wirkmechanismen. In: Riederer P, Laux G, Pöldinger W (Hrsg): Neuropsychopharmaka, Bd. 4: Neuroleptica. Springer-Verlag, Wien New York, S. 185–196.

    Google Scholar 

  • Laakmann G, Schüle C, Baghai T, Kieser M (1998): St. John’s wort in mild to moderate depression: The relevance of hyperforin for clinical efficacy. Pharmacopsychiatry 31(Suppl): 54–59.

    Article  PubMed  CAS  Google Scholar 

  • Lapierre YD (1989): A review of trimipramine 30 years of clinical use. Drugs 38(suppl 1): 17–24.

    Article  PubMed  Google Scholar 

  • Laties AM (2002): Quetiapine and cataracts. Am J Psychiatry 159: 322–323.

    Article  PubMed  Google Scholar 

  • Laux G, Volz H-P, Möller H-J (1995): Newer and older monoamine oxidase inhibitors. CNS Drugs 3:145–158.

    Article  CAS  Google Scholar 

  • Lantz MS, Buchalter E, Giambanco V (1999): St. John’s wort and antidepressant drug interactions in the elderly. J Geriatr Psychiatry Neurol 12: 7–10.

    Article  PubMed  CAS  Google Scholar 

  • Lehmann K, Müller-Oerlinghausen B (1993): Kosten-/Nutzen-Kalkulation der Lithium-Langzeit-Prophylaxe. Klin Pharmakol Aktuell 4:68–70.

    Google Scholar 

  • Lepine JP, Gastpar M, Mendlewicz J, Tylee A (1997): Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 12:19–29.

    Article  PubMed  CAS  Google Scholar 

  • Lesch OM, Riegler A, Gutierrez K, Hertling I, Ramskogler K, Semler B et al (2001): The European acamprosate trials. Conclusions for research and therapy. J Biomed Sci 8:89–95.

    Article  PubMed  CAS  Google Scholar 

  • Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM (2003a): Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 160:1209–1222.

    Article  PubMed  Google Scholar 

  • Leucht S, Wahlbeck K, Hamann J, Kissling W (2003b): New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361:1581–1589.

    Article  PubMed  CAS  Google Scholar 

  • Linde K, Mulrow CD (2000): St. John’s wort for depression. Cochrane Database Syst Rev 2000(2):CD000448.

    Google Scholar 

  • Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D (1996): St John’s wort for depression — an overview and meta-analysis of randomised clinical trials. Brit Med J 313: 253–258.

    Article  PubMed  CAS  Google Scholar 

  • Linden M, Gothe H (1993): Benzodiazepine substitution in medical practice. Analysis of pharmacoepidemiological data based on expert interviews. Pharmacopsychiatry 26:107–113.

    Article  PubMed  CAS  Google Scholar 

  • MacGillivray S, Arroll B, Hatcher S, Ogston S, Reid I, Sullivan F et al (2003): Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. Brit Med J 326:1014–1019.

    Article  PubMed  CAS  Google Scholar 

  • Macritchie KAN, Geddes MR, Scott J, Haslam DRS, Goodwin GM (2001): Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorders. Cochrane Review. In: The Cochrane Library Issue 3. Oxford, Updated Software.

    Google Scholar 

  • Marder SR, Meibach RC (1994): Risperidone in the treatment of schizophrenia. Am J Psychiatry 151: 825–835.

    PubMed  CAS  Google Scholar 

  • Melkersson K, Dahl ML (2004): Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 64: 701–723.

    Article  PubMed  CAS  Google Scholar 

  • Möller H-J (1999): Atypical neuroleptics: a new approach in the treatment of negative symptoms. Eur Arch Psychiatry Clin Neurosci 249(Suppl 4): 99–107.

    Article  PubMed  Google Scholar 

  • Möller H-J, Volz HP, Reimann IW, Stoll KD (2001): Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. J Clin Psychopharmacol 21: 59–65.

    Article  PubMed  Google Scholar 

  • Moncrieff J (2001): Are antidepressants overrated? A review of methodological problems in antidepressant trials. J Nerv Ment Dis 189:288–295.

    Article  PubMed  CAS  Google Scholar 

  • Montgomery SA, Roberts A, Patel AG (1994): Placebo-controlled efficacy of antidepressants in continuation treatment. Int Clin Psychopharmacology 9:49–53.

    Article  Google Scholar 

  • Montgomery S, Ferguson JM, Schwartz GE (2003): The antidepressant efficacy of reboxetine in patients with severe depression. J Clin Psychopharmacol 23:45–50.

    Article  PubMed  CAS  Google Scholar 

  • Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM et al (2000): St. John’s wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 97: 7500–7502.

    Article  PubMed  CAS  Google Scholar 

  • Moses EL, Mallinger AG (2000): St. John’s wort: three cases of possible mania induction. J Clin Psychopharmacol 20:115–117.

    Article  PubMed  CAS  Google Scholar 

  • MTA Cooperative Group (1999): A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiat 56: 1073–1086.

    Article  Google Scholar 

  • Müller-Oerlinghausen B (2001): Abhängigkeit und Mißbrauch von Substanzen. Dtsch Ärztebl 98: A1625–A1627.

    Google Scholar 

  • Müller-Oerlinghausen B, Berghöfer A (1999): Antidepressants and suicidal risk. J Clin Psychiatry 60(suppl 2): S94–S99.

    Google Scholar 

  • Müller-Oerlinghausen B, Berghöfer A, Ahrens B (2003): The antisuicidal and mortality-reducing effect of lithium prophylaxis: consequences for guidelines in clinical psychiatry. Can J Psychiatry 48:433–439.

    PubMed  Google Scholar 

  • Müller-Oerlinghausen B, Berghöfer A, Bauer M (2002): Bipolar disorder. Lancet 359: 241–247.

    Article  PubMed  Google Scholar 

  • Müller-Oerlinghausen B, Greil W, Berghöfer A (Hrsg) (1997): Die Lithiumtherapie. Nutzen Risiken Alternativen. Springer-Verlag, Berlin Heidelberg New York.

    Google Scholar 

  • Nierenberg AA, Burt T, Matthews J, Weiss AP (1999): Mania associated with St. John’s wort. Biol Psychiatry 46: 1707–1708.

    Article  CAS  Google Scholar 

  • Oeljeschläger B, Müller-Oerlinghausen B (2004): Wege zur Optimierung der individuellen antidepressiven Therapie. Deutsches Ärzteblatt 101: A 1337–1340.

    Google Scholar 

  • Olfson M, Marcus SC, Pincus HA, Zito JM, Thompson JW, Zarin DA (1998): Anti-depressant prescribing practices of outpatient psychiatrists. Arch Gen Psychiatry 55: 310–316.

    Article  PubMed  CAS  Google Scholar 

  • Parker V, Wong AH, Boon HS, Seeman MV (2001): Adverse reactions to St John’s wort. Can J Psychiatry 46: 77–79.

    PubMed  CAS  Google Scholar 

  • Philipp M, Kohnen R, Hiller KO (1999): Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. Brit Med J 319:1534–1538.

    Article  PubMed  CAS  Google Scholar 

  • Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J (2000): Indinavir concentrations and St John’s wort. Lancet 355: 547–548.

    Article  PubMed  CAS  Google Scholar 

  • Rickels K, Rynn M (2002): Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 63(Suppl 14): 9–16.

    PubMed  CAS  Google Scholar 

  • Riederer P, Laux G, Pöldinger W (Hrsg) (1993): Neuropsychopharmaka Bd. 3 Antidepressiva und Phasenprophylaktika. Springer-Verlag, Wien New York.

    Google Scholar 

  • Rüther E, Degner D, Munzel U, Brunner E, Lenhard G, Biehl J, Vogtle-Junkert U (1999): Antidepressant action of sulpiride. Results of a placebo-controlled double-blind trial. Pharmacopsychiatry 32:127–135.

    Article  PubMed  Google Scholar 

  • Ruschitzka F, Meier PJ, Turina M, Lüscher TF, Noll G (2000): Acute heart transplant rejection due to Saint John’s wort. Lancet 355: 548–549.

    Article  PubMed  CAS  Google Scholar 

  • Safer DJ (2000): Are stimulants overprescribed for youths with ADHD? Ann Clin Psychiatry 12: 55–62.

    PubMed  CAS  Google Scholar 

  • Sass H, Soyka M, Mann K, Zieglgansberger W (1996): Relapse prevention by acam-prosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 53:673–680.

    Article  PubMed  CAS  Google Scholar 

  • ’schizophrenia and Diabetes 2003’ Expert Consensus Meeting, Dublin, 3–4 October 2003: consensus summary. Br J Psychiatry 184(suppl 47): s112–s114.

    Google Scholar 

  • Schnyder U, Koller-Leiser A (1996): A double-blind, multicentre study of paroxetine and maprotiline in major depression. Can J Psychiatry 41: 239–244.

    PubMed  CAS  Google Scholar 

  • Schou M (1998): Has the time come to abandon prophylactic lithium treatment? A review for clinicians. Pharmacopsychiatry 31: 210–215.

    Article  PubMed  CAS  Google Scholar 

  • Schrader E (2000): Equivalence of St John’s wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int Clin Psycho-pharmacol 15: 61–68.

    Article  CAS  Google Scholar 

  • Schulz V, Hänsel R (Hrsg) (1996): Rationale Phytotherapie. Ratgeber für die ärztliche Praxis. Springer-Verlag, Berlin Heidelberg New York.

    Google Scholar 

  • Shelton RC, Keller MB, Gelenberg A, Dunner DL, Hirschfeld R, Thase ME et al (2001): Effectiveness of St John’s wort in major depression: a randomized controlled trial. JAMA 285:1978–1986.

    Article  PubMed  CAS  Google Scholar 

  • Smith D, Dempster C, Glanville J, Freemantle N, Anderson I (2002): Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 180: 396–404.

    Article  PubMed  Google Scholar 

  • Snow V, Lascher S, Mottur-Pilson C, for the American College of Physicians —American Society of Internal Medicine (2000): Clinical guideline I. Pharmacological treatment of acute major depression and dysthymia. Ann Int Med 132: 739–742.

    Google Scholar 

  • Spigset O, Hagg S, Bate A (2003): Hepatic injury and pancreatitis during treatment with serotonin reuptake inhibitors: data from the World Health Organization (WHO) database of adverse drug reactions. Int Clin Psychopharmacol 18: 157–161.

    PubMed  Google Scholar 

  • Sramek JJ, Zarotsky V, Cutler NR (2002): Generalized anxiety disorder: treatment options. Drugs 62: 1635–1648.

    Article  PubMed  CAS  Google Scholar 

  • Stewart DE (2002): Hepatic adverse reactions associated with nefazodone. Can J Psychiatry 47: 375–377.

    PubMed  Google Scholar 

  • Stip E (2000): Novel antipsychotics: issues and controversies. Typicality of atypical neuroleptics. J Psychiatry Neurosci 25:137–153.

    PubMed  CAS  Google Scholar 

  • Sugimoto K, Ohmori M, Tsuruoka S, Nishiki K, Kawaguchi A, Harada K et al (2001): Different effects of St John’s wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 70: 518–524.

    Article  PubMed  CAS  Google Scholar 

  • Swift RM (1999): Drug therapy for alcohol dependence. N Engl J Med 340: 1482–1490.

    Article  PubMed  CAS  Google Scholar 

  • Tandon R, Jibson MD (2003): Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 28: 9–26.

    Article  PubMed  CAS  Google Scholar 

  • Taylor DM, McAskill R (2000): Atypical antipsychotics and weight gain — a systematic review. Acta Psychiatr Scand 101: 416–432.

    Article  PubMed  CAS  Google Scholar 

  • Tempesta E, Janiri L, Bignamini A, Chabac S, Potgieter A (2000): Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol 35: 202–209.

    PubMed  CAS  Google Scholar 

  • Thase ME (2003): Effectiveness of antidepressants: comparative remission rates. J Clin Psychiatry 64(Suppl 2): 3–7.

    CAS  Google Scholar 

  • Thase ME, Entsuah R, Rudolph RL (2001a): Remission rates during treatment with venlafaxine or selective reuptake inhibitors. Br J Psychiatry 178:234–241.

    Article  PubMed  CAS  Google Scholar 

  • Thase ME, Nierenberg AA, Keller MB, Panagides J (2001b): Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients. J Clin Psychiatry 62: 782–788.

    Article  PubMed  CAS  Google Scholar 

  • Tohen M, Chengappa KN, Suppes T, Baker RW, Zarate CA et al (2004): Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabilizer v. mood stabilizer alone. Br J Psychiatry 184: 337–345.

    Article  PubMed  Google Scholar 

  • Trindade E, Menon D, Topfer LA, Coloma C (1998): Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a metaanalysis. Canad Med Ass J 159:1245–1252.

    CAS  Google Scholar 

  • Van Walraven CMamdani MM, Wells PS, Williams JI (2001) Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. Brit Med J 323:1–6.

    Article  Google Scholar 

  • Volovka J, Czobor P, Cooper TB, Sheitman B, Lindenmayer JP et al (2004): Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or Haloperidol. J Clin Psychiatry 65: 57–61.

    Article  Google Scholar 

  • Volz HP, Gleiter CH, Möller HJ (1996): Monoaminoxidasehemmer in der Psychiatric. Nervenarzt 67: 339–347.

    PubMed  CAS  Google Scholar 

  • Volz HP, Möller HJ, Reimann I, Stoll K (2000): Opipramol for the treatment of somatoform disorders. Results from a placebo-controlled trial. Eur Neuro-psychopharmacol 10: 211–217.

    Article  CAS  Google Scholar 

  • Von Ferber L, Lehmkuhl G, Köster I, Döpfner M, Schubert I, Frölich J, Ihle P (2003): Methylphenidatgebrauch in Deutschland. Dtsch Ärztebl 100: C38–C43.

    Google Scholar 

  • Walsh BT, Seidman SN, Sysko R, Gould M (2002): Placebo response in studies of major depression. Variable, substantial and growing. JAMA 287:1840–1847.

    Article  PubMed  Google Scholar 

  • Wang Z, Hamman MA, Huang SM, Lesko LJ, Hall SD (2002): Effect of St John’s wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 71:414–420.

    Article  PubMed  CAS  Google Scholar 

  • Wetterling T (2001): Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf 24:59–73.

    Article  PubMed  CAS  Google Scholar 

  • Whittington CJ, Kendall T, Fonagy P, Cottrell D, Colgrove A, Boddington E (2004): Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 363:1341–1345.

    Article  PubMed  CAS  Google Scholar 

  • Williams JW Jr, Mulrow CD, Chiquette E, Hitchcock Noel P, Aguilar C, Cornell J (2000): Clinical guideline, part 2. A systematic review of newer pharmacotherapies for depression in adults: Evidence report summary. Ann Intern Med 132: 743–756.

    PubMed  CAS  Google Scholar 

  • Woelk H (2000): Comparison of St John’s wort and Imipramine for treating depression: randomised controlled trial. Brit Med J 321: 536–539.

    Article  PubMed  CAS  Google Scholar 

  • Woods JH, Winger G (1995): Current benzodiazepine issues. Psychopharmacology 118:107–115.

    Article  PubMed  CAS  Google Scholar 

  • Yue Q-Y, Bergquist C, Gerdén B (2000): Safety of St John’s wort (Hypericum perforatum). Lancet 355: 576–577.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Pharmakologie und Toxikologie der Universität Würzburg, Versbacher Straße 9, 97078, Würzburg

    Prof. Dr. med. Martin J. Lohse

  2. Psychiatrisches Zentrum Nordbaden, Zentrum für Psychiatrie Wiesloch, Heidelberger Str. 1a, 69168, Wiesloch

    Privatdozentin Dr. med. Anna Lorenzen

  3. Jebenstraße 3, 10623, Berlin

    Prof. Dr. med. Bruno Müller-Oerlinghausen

Authors
  1. Prof. Dr. med. Martin J. Lohse
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Privatdozentin Dr. med. Anna Lorenzen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Prof. Dr. med. Bruno Müller-Oerlinghausen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Lohse, M.J., Lorenzen, A., Müller-Oerlinghausen, B. (2004). Psychopharmaka. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2004. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18513-7_43

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-18513-7_43

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-21359-8

  • Online ISBN: 978-3-642-18513-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation